The First Dose Is Everything: How Noble’s SureStartRx™ Program Improves Adherence and Persistence

The first dose of a self-injectable therapy is a critical moment that often determines whether patients move forward with treatment or abandon it due to uncertainty. Noble’s SureStartRx™ program addresses this challenge by sending remote demonstration kits through specialty pharmacies, allowing patients to practice injections and build confidence before their first dose. Research shows that when demonstration kits are added to standard support, patients initiate therapy sooner, adhere better in the short term, and stay on treatment longer. In this discussion, Noble’s Director of Patient Engagement Services, Sean Glynn, explains how improving patient confidence at the start of therapy can protect both patient outcomes and long-term brand value.

Key Objectives

• Understand why the first dose is a critical driver of patient adherence and persistence in self-injectable therapies.
• Explore the impact early therapy abandonment has on patient outcomes and brand performance.
• Learn how demonstration-based onboarding programs like SureStartRx™ can improv the overall patient experience.

DOWNLOAD Q&A